Medication Adherence and Health-Related Quality of Life in Patients With Breast Cancer Receiving Oral Anticancer Therapy: A Prospective Observational Study

Abstract Purpose This study evaluated medication adherence among patients with breast cancer receiving oral systemic anticancer therapy and examined its associations with sociodemographic, clinical, treatment-related, and health-related quality-of-life characteristics. Methods This prospective cross-sectional study included 95 patients receiving aromatase inhibitor-based therapy, tamoxifen-based therapy, or cyclin-dependent kinase 4/6 inhibitor-based combination therapy. Medication adherence and health-related quality of life were assessed using the eight-item Morisky Medication Adherence Scale (MMAS-8) and EORTC QLQ-C30, respectively. MMAS-8 scores of < 6 and ≥ 6 indicated lower and higher adherence. Binary logistic regression was used to identify factors independently associated with higher adherence. Results Overall, 33 patients (34.7%) had lower adherence and 62 (65.3%) had higher adherence. Disease duration was longer in the lower-adherence group (median, 4.0 vs. 3.0 years; p = 0.029). Adherence differed according to treatment intent ( p = 0.013), medication group ( p = 0.048), and alcohol use status ( p = 0.002). Higher adherence was associated with better global health status and physical, emotional, cognitive, and social functioning and with lower fatigue, pain, dyspnoea, insomnia, and financial difficulties. The median QLQ-C30 Summary Score was higher in the higher-adherence group (80.00 vs. 68.89; p < 0.001). In the multivariable analysis of 80 complete cases, each 10-point increase in the Summary Score was associated with higher odds of higher adherence (adjusted odds ratio, 2.389; 95% confidence interval, 1.488–3.837; p < 0.001). Conclusion Better health-related quality of life was independently associated with higher medication adherence. Concurrent assessment of adherence and quality of life may help identify patients requiring further evaluation and supportive care.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-03
DOI
https://doi.org/10.21203/rs.3.rs-11157558/v1
Primary Topic
Medication Adherence and Compliance
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
preprint

Medication Adherence and Health-Related Quality of Life in Patients With Breast Cancer Receiving Oral Anticancer Therapy: A Prospective Observational Study

Onur Yazdan Balçık, İsmail Beypınar, Mustafa Sinanoglu, Gökçe Kavak Sinanoğlu et al.
Research Square
Medication Adherence and Compliance
preprint

Medication Adherence and Health-Related Quality of Life in Patients With Breast Cancer Receiving Oral Anticancer Therapy: A Prospective Observational Study

Onur Yazdan Balçık, İsmail Beypınar, Mustafa Sinanoglu, Gökçe Kavak Sinanoğlu, Tuğçe Erdoğan
preprint en

Abstract

Abstract Purpose This study evaluated medication adherence among patients with breast cancer receiving oral systemic anticancer therapy and examined its associations with sociodemographic, clinical, treatment-related, and health-related quality-of-life characteristics. Methods This prospective cross-sectional study included 95 patients receiving aromatase inhibitor-based therapy, tamoxifen-based therapy, or cyclin-dependent kinase 4/6 inhibitor-based combination therapy. Medication adherence and health-related quality of life were assessed using the eight-item Morisky Medication Adherence Scale (MMAS-8) and EORTC QLQ-C30, respectively. MMAS-8 scores of < 6 and ≥ 6 indicated lower and higher adherence. Binary logistic regression was used to identify factors independently associated with higher adherence. Results Overall, 33 patients (34.7%) had lower adherence and 62 (65.3%) had higher adherence. Disease duration was longer in the lower-adherence group (median, 4.0 vs. 3.0 years; p = 0.029). Adherence differed according to treatment intent ( p = 0.013), medication group ( p = 0.048), and alcohol use status ( p = 0.002). Higher adherence was associated with better global health status and physical, emotional, cognitive, and social functioning and with lower fatigue, pain, dyspnoea, insomnia, and financial difficulties. The median QLQ-C30 Summary Score was higher in the higher-adherence group (80.00 vs. 68.89; p < 0.001). In the multivariable analysis of 80 complete cases, each 10-point increase in the Summary Score was associated with higher odds of higher adherence (adjusted odds ratio, 2.389; 95% confidence interval, 1.488–3.837; p < 0.001). Conclusion Better health-related quality of life was independently associated with higher medication adherence. Concurrent assessment of adherence and quality of life may help identify patients requiring further evaluation and supportive care.

Research Square
Alanya Alaaddin Keykubat Üniversitesi (TR)
Medication Adherence and Compliance
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon